Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Snail Venom Sting in Tail of Cancer, Addiction

By Drug Discovery Trends Editor | January 8, 2015

The RegIIA toxin in molecular form superimposed on a cone snail. Cone snail venom could lead to better detection and treatment of some cancers and addictions. (Credit: University of Queensland)Cone snail venom has given University of Queensland researchers a lead on the possible detection and treatment of some cancers and addictions.
 
UQ School of Biomedical Sciences’ Dr Richard Clark said cone snails produced a venom that immobilised prey including worms, other snails and fish.
 
“This venom contains hundreds of different toxins that are highly potent and target specific receptors in their prey,” he said.
 
“The power and selectivity of these toxins make them both valuable drug leads and excellent molecular tools for understanding the human body’s processes.
 
Dr Clark said some of the toxins targeted the nicotinic acetylcholine receptor (nAChR) family.
 
“These receptors in the nervous system play diverse roles and have been implicated in a range of diseases including Alzheimer’s disease, schizophrenia, tobacco addiction and lung cancer.”
 
Dr Clark said the activation of one type of nAChR receptor, alpha3beta4, had been associated with lung cancer and nicotine addiction.
 
“However, understanding of this process has been limited and it has been shown in previous studies that a specific toxin from the cone snail venom inactivated the alpha3beta4 nAChR but also inactivated other types of nAChR,” he said.
 
“Our study focused on a specific toxin and we investigated its structure and how it worked to see if we could engineer a molecule that would only target the receptor associated with cancers and addictions.
 
“We were able to do this and it can now be used as a tool for studying these diseases.
 
“It might also be a potential drug lead once more is known about the role of the receptor in these conditions.”
 
The study, published in The Journal of Biological Chemistry, was done in collaboration with Royal Melbourne Institute of Technology’s Professor David Adams and Dr Frank Mari from the Florida Atlantic University in the USA.
 
Source: University of Queensland

Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE